Company intelligence / Profile preview

Sooma Medical

Ownership: Private
Employees: ~50
Development stage: Commercial

Overview

Sooma Medical has developed the first MDR-approved transcranial direct current stimulation (tDCS) system for depression and chronic pain. Over 25,000 patients have been treated globally. In peer-reviewed studies, up to 55% of patients with major depressive disorder experienced symptom relief within three weeks. The company’s tDCS devices are used by more than 150 clinics across over 35 countries. A pivotal FDA IDE trial for at-home depression treatment began recently following Breakthrough Device Designation from the FDA.

Therapeutic areas: PsychiatryRheumatologyNeurology
Modalities: DeviceNon-pharmacological therapy (Transcranial Direct Current Stimulation)Neuromodulation device
Industry: Therapeutic Medical Devices

Partnerships

Lindus Health – clinical trials partner for pivotal U.S. study on at-home depression treatment device

Beyond the preview

Go deeper on Sooma Medical.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Sooma Medical.

Explore the full profile